References
- Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat 2013;9:1257–66
- Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173–6
- Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatr 2004;65:230–7
- Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009;31:404–9
- Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatr 2010;44:978–96
- Jordan AE, Jackson GL, Deardorff D, et al. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. J Matern Fetal Neonatal Med 2008;21:745–51
- Ververs T, Kaasenbrood H, Visser G, et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62:863–70
- Ray S, Stowe ZN. The use of antidepressant medication in pregnancy. Best Pract Res Clin Obstet Gynaecol 2014;28:71–83
- Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci 2008;45:107–13
- Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372–83
- Sie SD, Wennink JMB, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Archiv Dis Childhood - Fetal Neonat Ed 2012;97:F472-6
- Ferreira E, Carceller AM, Agogue C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007;119:52–9
- Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482–7
- Sit D, Perel JM, Wisniewski SR, et al. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatr 2011;72:994–1001
- Finnegan LP, Connaughton JF, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141–58
- Horst Ter PGJ, Jansman FGA, van Lingen RA, et al. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 2008;63:267–79
- Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012;129:e540–60
- Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006;26:15–17
- Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47–55
- Hosmer D, Lemeshow S. Applied logistic regression, 2nd ed. New York: John Wiley & Sons